Inspire Medical Systems: Analysts Lower Price Target to $97 Amid Recent Rating Actions

Leerink Partners has maintained its "Market Perform" rating for Inspire Medical Systems (INSP) while lowering the price target from $116 to $97. This represents a -16.38% change. The average analyst target price for INSP is $148.24, with a high estimate of $230 and a low estimate of $101. The average brokerage recommendation is 2.4, indicating an "Outperform" status. The estimated GF Value for INSP in one year is $304.74, suggesting a 260.3% upside from the current price of $84.58.

Leerink Partners has maintained its "Market Perform" rating for Inspire Medical Systems (INSP) while lowering the price target from $116 to $97. This adjustment represents a significant -16.38% change in the price target. The move reflects the brokerage firm's assessment of Inspire Medical Systems' recent financial performance and the challenges it faces in the commercial rollout of its Inspire V system [1].

The average analyst target price for INSP is currently $148.24, with a high estimate of $230 and a low estimate of $101. This indicates a broad range of expectations among financial experts. Despite the downward trend in the price target, the average brokerage recommendation remains 2.4, suggesting an "Outperform" status. This discrepancy highlights the varying opinions among analysts regarding the company's future prospects.

The estimated GF Value for INSP in one year is $304.74, suggesting a substantial 260.3% upside from the current price of $84.58. This estimate is based on the company's expected future performance and the potential for growth in its sleep apnea treatment market.

Inspire Medical Systems has been facing operational challenges tied to the commercial rollout of its Inspire V system, including slower-than-expected transitions at implanting centers and delayed Medicare billing. These issues have contributed to a cautious tone from management and a significant negative market reaction to the company's Q2 earnings [1]. However, management remains optimistic about the company's long-term prospects and expects growth to accelerate in 2026 as Inspire V adoption normalizes and backlog is addressed.

Investors should closely monitor Inspire Medical Systems' progress in transitioning additional centers to Inspire V, the effectiveness of its patient marketing efforts, and improvements in surgical capacity and throughput at transitioned centers. Additionally, updates on Medicare reimbursement and the competitive landscape for sleep apnea treatments will be crucial factors to watch in the coming quarters.

References:
[1] https://finance.yahoo.com/news/inspire-medical-systems-q2-earnings-040153921.html
[2] https://www.benzinga.com/insights/analyst-ratings/25/08/47165861/13-analysts-have-this-to-say-about-inspire-medical-systems